Imjudo (tremelimumab-actl) — Medica

Initial criteria

• age ≥ 18 years
• liver-confined unresectable disease with patient deemed ineligible for transplant OR extrahepatic or metastatic disease with patient deemed ineligible for resection, transplant, or locoregional therapy
• used as first-line systemic therapy
• used in combination with Imfinzi (durvalumab intravenous infusion)
• prescribed by or in consultation with an oncologist

Approval duration

30 days